Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-1 Registration statement (foreign)
- 3.1 Second Amended and Restated Memorandum and Articles of Association of Aptorum Group Limited
- 4.1 Specimen Ordinary Share Certificate
- 4.2 Form of Series a Convertible Promissory Note
- 10.1 Appointment Letter Between the Company and Ian Huen (Founder, Chief Executive Officer & Executive Director), Dated September 25, 2017
- 10.2 Employment Letter Between the Company and Sabrina Khan (Chief Financial Officer), Dated September 1, 2017
- 10.3 Addendum to Employment Letter Between Company and Sabrina Khan (Chief Financial Officer) Dated April 24, 2018
- 10.4 Appointment Letter Between the Company and Darren Lui (Chief Business Officer, President & Director), Dated September 25, 2017
- 10.5 Employment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated August 31, 2017
- 10.6 Addendum to Appointment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated September 25, 2017
- 10.7 Second Addendum to Appointment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated October 30, 2017
- 10.8 Third Addendum to Appointment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated January 2, 2018
- 10.9 Appointment Letter Between the Company and Keith Chan (Chief Scientific Officer), Dated August 18, 2017
- 10.10 Appointment Letter Between the Company and Charles Bathurst (Independent Non-executive Director), Dated September 24, 2017
- 10.11 Appointment Letter Between the Company and Mirko Scherer (Independent Non-executive Director), Dated September 24, 2017
- 10.12 Employment Agreement Between the Company and Justin Wu (Independent Non-executive Director), Dated September 18, 2017
- 10.13 Employment Agreement Between the Company and Douglas Arner (Independent Non-executive Director), Dated February 13, 2018
- 10.14 Management Agreement Between the Company and Guardian Capital Management Limited, Dated March 1, 2017
- 10.15 Consulting Agreement Between the Company and Globoasia, LLC (Includes Provisions for the Appointment of Keith Chan As Chief Scientific Officer) Dated August 18, 2017
- 10.16 Management Agreement Between the Company and Aptus Capital Limited, Dated October 26, 2010
- 10.17 First Addendum to the Management Agreement Between the Company and Aptus Capital Limited, Dated February 10, 2012
- 10.18 Second Addendum to the Management Agreement Between the Company and Aptus Capital Limited, December 9, 2016
- 10.19 Subscription Agreement Between the Company and Peace Range Limited, Dated April 6, 2018
- 10.20 Share Charge Agreement Between the Company, Jurchen Investment Corporation and Peace Range Limited, Dated April 25, 2018
- 10.21 Deed of Guarantee of Jurchen Investment Corporation, Acknowledged by Peace Range Limited, Dated April 25, 2018
- 10.22 Charge Account Agreement Between the Company and Peace Range Limited, Dated April 25, 2018
- 10.23 Bond Certificate Between the Company and Peace Range Limited, Dated April 25, 2018
- 10.24 Escrow Agreement Between the Company and Peace Range Limited, Dated April 25, 2018
- 10.25 2017 Share Option Plan
- 10.26 Form of Securities Purchase Agreement for the Series a Convertible Promissory Notes, Dated May 15, 2018
- 10.27 Lock-up Agreement for Series a Convertible Promissory Notes, Dated May 15, 2018
- 10.28 Exclusive License Agreement for NLS-1 Dated July 3, 2017
- 10.29 Addendum to License Agreement for NLS-1 Dated February 9, 2018
- 10.30 Exclusive Patent License Agreement for ALS-1
- 10.31 First Amendment to the Exclusive Patent License Agreement for ALS-1 Dated June 7, 2018
- 10.32 Exclusive Patent License Agreement for ALS-4
- 10.33 First Amendment to the Exclusive Patent License Agreement Dated June 7, 2018
- 10.34 Sub-tenancy Agreement for Guangdong Investment Tower
- 10.35 Service Agreement Between Covar Pharmaceuticals Incorporated and Videns Incorporation Limited Dated May 15, 2017
- 10.36 Appointment Letter and Addendum to Service Agreement with Covar Pharmaceuticals Incorporated and DR. Kwok Chow Dated December 15, 2017
- 10.37 Appointment Letter and Addendum to Service Agreement with Covar Pharmaceuticals Incorporated and MR. Austin Freedman Dated December 26, 2017
- 14.1 Code of Business Conduct and Ethics of the Company
- 21.1 List of Subsidiaries
- 23.1 Consent of Marcum Bernstein & Pinchuk LLP
- 99.1 Charter of the Audit Committee
- 99.2 Charter of the Compensation Committee
- 99.3 Charter of the Nominating and Corporate Governance Committee
APM similar filings
Filing view
External links